在PrEP影响试验中,HIV血清转化和基因型病毒耐药性概况
Andrea Cartier1, Ana Milinkovic1,2, Lisa Goodall3
1Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
HIV medicine
|May 22, 2025
概括
口服暴露前预防 (PrEP) 含有与emtricitabine (TDF/FTC) 联合的tenofovir disoproxil maleate是预防艾滋病毒的有效方法. 在PrEP影响试验期间血清转换的参与者中,耐药性很低.
科学领域:
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
- 临床试验 临床试验
背景情况:
- 在PrEP影响试验中,评估了艾滋病毒预防策略.
- 了解HIV血清转化事件对于公共卫生倡议至关重要.
研究的目的:
- 描述PrEP影响试验参与者的HIV血清转化事件.
- 评估试验中HIV诊断的发病率和特征.
主要方法:
- 审查了24268名参与者的数据.
- 专注于54名参与者在试验期间被诊断为艾滋病毒感染者,其中包括11名在基线.
主要成果:
- 在大流行前的诊断中,艾滋病毒发病率很低 (100人/年0.13人),通常与缺乏坚持相关.
- 在最近接受口服PrEP (TDF / FTC) 的参与者中,药物耐药性的出现很低 (21%) 并且有血清转化.
结论:
- 口服PrEP (TDF/FTC) 证明了作为一种艾滋病毒预防干预措施的有效性.
- 需要进一步的研究来评估口服PrEP广泛使用对HIV耐药性模式的影响.
相关概念视频
Retrovirus Life Cycles
45.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.5K
Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K


